Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $796.85M | $30.44M | $0.09 |
| 2024 | $792.32M | $16.39M | $0.04 |
| 2023 | $750.26M | $-8.87M | $-0.02 |
| 2022 | $766.55M | $-32.83M | $-0.08 |
| 2021 | $745.42M | $-25.25M | $-0.06 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $0.08 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.08 vs $0.08beat
- Wed, May 6$0.07 vs $0.07beat
- Wed, Feb 25$0.09 vs $0.09beat
- Tue, Nov 4$0.08 vs $0.09miss
- Wed, Aug 6$0.09 vs $0.10miss
- Wed, May 7$0.09 vs $0.09beat
Estimates and results for GDRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.13
- Implied price
- $4.02
- Return from $3.73
- 1.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.00 — -46.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 22 | 27 | 32 | 37 | 42 |
|---|---|---|---|---|---|
| -2.0% | -14.6% | -11.0% | -7.9% | -5.2% | -2.8% |
| 3.0% | -10.2% | -6.4% | -3.2% | -0.4% | 2.2% |
| 8.0% | -5.8% | -1.9% | 1.5% | 4.5% | 7.2% |
| 13.0% | -1.5% | 2.6% | 6.2% | 9.3% | 12.1% |
| 18.0% | 2.9% | 7.2% | 10.9% | 14.2% | 17.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsseekingalpha.com·3d ago·Positive
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
View source ↗